Scarica l'app Stockscreener
5.68
8.83%
-0.55
Dopo l'orario di chiusura:
5.70
0.02
+0.35%
Precedente Chiudi:
$6.23
Aprire:
$6.28
Volume 24 ore:
5.57M
Relative Volume:
1.41
Capitalizzazione di mercato:
$764.38M
Reddito:
-
Utile/perdita netta:
$-217.44M
Rapporto P/E:
-2.6175
EPS:
-2.17
Flusso di cassa netto:
$-205.20M
1 W Prestazione:
-10.13%
1M Prestazione:
+46.02%
6M Prestazione:
+385.47%
1 anno Prestazione:
+58.66%
Intervallo 1D:
$5.50
$6.42
Intervallo di 1 settimana:
$5.50
$6.94
Portata 52W:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Confronta PRME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
5.68 | 1.11B | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
Prime Medicine (NASDAQ:PRME) Stock Price Down 5.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 3.4%Here's What Happened - MarketBeat
Quantitative breakdown of Prime Medicine Inc. recent move2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Using AI based signals to follow Prime Medicine Inc.Market Growth Summary & Short-Term Trading Opportunity Alerts - newser.com
Is it too late to sell Prime Medicine Inc.July 2025 Short Interest & Short-Term High Return Strategies - newser.com
Prime Medicine Soars 9.88% to Day High of $6.85 Amid Strong Intraday Performance - Markets Mojo
Is Prime Medicine Inc. stock entering bullish territoryWeekly Stock Report & High Return Trade Guides - newser.com
How to recover losses in Prime Medicine Inc. stockMarket Risk Report & Daily Stock Momentum Reports - newser.com
Volume spikes in Prime Medicine Inc. stock – what they mean2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Volatility clustering patterns for Prime Medicine Inc.July 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
Prime Medicine (NASDAQ:PRME) Stock Price Up 11.6%Should You Buy? - MarketBeat
Prime Medicine (NYSE:PRME) Shares Up 7.8%Still a Buy? - MarketBeat
Prime Medicine, Inc. Hits New 52-Week High of $6.94 - Markets Mojo
Prime Medicine, Inc. Hits New 52-Week High of $6.92 - Markets Mojo
Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Prime Medicine (NASDAQ:PRME) Sets New 12-Month HighWhat's Next? - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
What earnings revisions data tells us about Prime Medicine Inc.July 2025 Patterns & Entry and Exit Point Strategies - newser.com
Is Prime Medicine Inc. stock a buy on dipsJuly 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-06 02:45:47 - newser.com
Using flow based indicators on Prime Medicine Inc.Quarterly Market Review & Momentum Based Trading Signals - newser.com
Measuring Prime Medicine Inc.’s beta against major indicesJuly 2025 Earnings & Weekly Chart Analysis and Guides - newser.com
Prime Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRME - Benzinga
Prime Medicine, Inc. Hits New 52-Week High of $5.82 - Markets Mojo
Short interest data insights for Prime Medicine Inc.July 2025 Trends & Stock Portfolio Risk Management - newser.com
Backtesting results for Prime Medicine Inc. trading strategiesJuly 2025 Volume & Smart Investment Allocation Insights - newser.com
Is Prime Medicine Inc a good long term investmentIPO Market Watch & Double Digit Wealth Tips - earlytimes.in
Prime Medicine (NYSE:PRME) Trading Up 8%What's Next? - MarketBeat
Prime Medicine Sees Strong Momentum Among Top Healthcare Stocks - Kalkine Media
Prime Medicine (NASDAQ:PRME) Hits New 1-Year HighTime to Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 3.9%Here's Why - MarketBeat
When is the best time to exit Prime Medicine Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - newser.com
Septerna appoints Keith Gottesdiener to board of directors - Investing.com India
Former Prime Medicine CEO and 20+ Drug Approval Leader Keith Gottesdiener Joins Septerna's Board - Stock Titan
Prime Medicine, Inc. Hits New 52-Week High of $5.20 - Markets Mojo
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prime Medicine Inc Azioni (PRME) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):